The protective effect of antioxidants on orbital fibroblasts from patients with Graves' ophthalmopathy in response to oxidative stress
- PMID: 23687429
- PMCID: PMC3654843
The protective effect of antioxidants on orbital fibroblasts from patients with Graves' ophthalmopathy in response to oxidative stress
Abstract
Purpose: To investigate the biphasic effects of hydrogen peroxide (H2O2) on the orbital fibroblasts of patients with Graves' ophthalmopathy (GO) and the relation to antioxidants and proinflammatory cytokines.
Methods: Proliferation of cultured orbital fibroblasts from patients with GO and normal controls was evaluated in response to various concentrations of H2O2. The effect of low concentrations of H2O2 (6.25 μM) on the cellular proliferation and induction of intracellular proinflammatory cytokines, and reactive oxygen species of orbital fibroblasts were assessed. Protective effects of N-acetylcysteine and vitamin C on GO fibroblasts in response to 6.25 μM H2O2 stimulation were also investigated.
Results: When the GO fibroblasts were exposed to H2O2 at a concentration of 50 μM or above, significant cytotoxicity was observed. In contrast, lower concentrations of H2O2 (3.125-25 μM) increased the survival of GO fibroblasts with the peak cellular proliferation at 6.25 μM H2O2. However, this biphasic effect of H2O2 on the viability of orbital fibroblasts was not found in normal controls. In addition, 6.25 μM H2O2 led to significant elevation of the levels of transforming growth factor, beta 1, interleukin-1β, and superoxide anion in GO fibroblasts, but no significant change in the normal controls. Pretreatment with N-acetylcysteine or vitamin C reversed the enhanced proliferation capacity and the induction of transforming growth factor, beta 1, interleukin-1β and superoxide anion of GO fibroblasts in response to 6.25 μM H2O2.
Conclusions: These findings revealed the biphasic effect of H2O2 on cellular proliferation of GO orbital fibroblasts. Importantly, a low level of H2O2 can stimulate proliferation of GO orbital fibroblasts and induce the production of proinflammatory cytokines, which can be inhibited by pretreatment with antioxidants. This provides a theoretical basis for the rational use of antioxidant in treating GO at an early stage.
Figures





Similar articles
-
Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy.Thyroid. 2017 Feb;27(2):271-278. doi: 10.1089/thy.2016.0397. Epub 2016 Dec 16. Thyroid. 2017. PMID: 27824294
-
Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO).J Endocrinol Invest. 2018 Jul;41(7):815-820. doi: 10.1007/s40618-017-0809-5. Epub 2017 Dec 18. J Endocrinol Invest. 2018. PMID: 29256181
-
Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?J Endocrinol Invest. 2018 Feb;41(2):193-201. doi: 10.1007/s40618-017-0718-7. Epub 2017 Jun 27. J Endocrinol Invest. 2018. PMID: 28656526
-
The orbital fibroblast: a key player and target for therapy in graves' ophthalmopathy.Orbit. 2010 Aug;29(4):202-6. doi: 10.3109/01676831003668443. Orbit. 2010. PMID: 20812837 Review.
-
Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.Exp Eye Res. 2016 Jan;142:83-91. doi: 10.1016/j.exer.2015.02.007. Exp Eye Res. 2016. PMID: 26675405 Review.
Cited by
-
Oxidative stress markers in tears of patients with Graves' orbitopathy and their correlation with clinical activity score.BMC Ophthalmol. 2018 Nov 21;18(1):303. doi: 10.1186/s12886-018-0969-x. BMC Ophthalmol. 2018. PMID: 30463536 Free PMC article.
-
Antioxidant Therapy in Graves' Orbitopathy.Front Endocrinol (Lausanne). 2020 Dec 14;11:608733. doi: 10.3389/fendo.2020.608733. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33381085 Free PMC article. Review.
-
Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease.Front Endocrinol (Lausanne). 2021 Jan 26;11:608428. doi: 10.3389/fendo.2020.608428. eCollection 2020. Front Endocrinol (Lausanne). 2021. PMID: 33574798 Free PMC article. Review.
-
Endoplasmic reticulum protein TXNDC5 modulates thyroid eye disease TGF-β1-induced myofibroblast transdifferentiation.BMJ Open Ophthalmol. 2024 Dec 25;9(1):e001693. doi: 10.1136/bmjophth-2024-001693. BMJ Open Ophthalmol. 2024. PMID: 39721966 Free PMC article.
-
A Systematic Review on the Role of Antioxidants in Thyroid Eye Disease.J Curr Ophthalmol. 2022 Apr 16;34(1):16-24. doi: 10.4103/joco.joco_266_21. eCollection 2022 Jan-Mar. J Curr Ophthalmol. 2022. PMID: 35620378 Free PMC article. Review.
References
-
- Kazim M, Goldberg RA, Smith TJ. Insights into the pathogenesis of thyroid associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol. 2002;120:380–6. - PubMed
-
- Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008;18:983–8. - PMC - PubMed
-
- Bartalena L, Tanda ML, Piantanida E, Lai A. Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors. 2003;19:155–63. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical